Senseonics (SENS) Registration Filing summary

Company overview and business model

• Focuses on developing and manufacturing implantable continuous glucose monitoring (CGM) systems for diabetes management, including Eversense E3 (180-day) and Eversense 365 (365-day) systems.

• Revenue is generated from sales of Eversense systems, including sensors, transmitters, and related procedure revenue.

• Early commercialization stage, leveraging strategic partnerships and distribution agreements to expand market reach in the US and Europe.

• Pipeline includes next-generation products such as Gemini (2-in-1 CGM/flash) and Freedom (Bluetooth-enabled sensor).

Financial performance and metrics

• As of June 30, 2025, 814,576,132 shares of common stock were outstanding.

• Net tangible book value as of June 30, 2025, was $94.0 million ($0.12 per share); offering could increase this to $191.1 million ($0.19 per share).

• Audit report includes a going concern warning due to cash position and debt covenant requirements.

Use of proceeds and capital allocation

• Proceeds will be used for general corporate purposes, including R&D, administrative, sales and marketing, and capital expenditures.

• May allocate funds to in-license, invest in, or acquire complementary businesses, assets, or technologies, though no current commitments exist.

• Management retains broad discretion over use of proceeds.